AI Article Synopsis
Article Abstract
Objective: To explore the predictors of hematologic responses of non-transfusion-dependent β-thalassemia (NTDT) to thalidomide.
Methods: 33 patients with NTDT who treated with thalidomide in the 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army from May 2016 to June 2019 were included in the study. The basic data, hematological indexes, degree of treatment response and genetic background of the patients were analyzed.
Results: The baseline fetal hemoglobin (HbF) level of main responders (MaR) was significantly higher than that of minor responders (MiR) and no responders (NR) (P=0.001). And the baseline HbF level was positively correlated with hemoglobin increment after treatment (r=0.601). Genetic background analysis showed that the frequencies of the genotype CT of HBG2 rs7482144 (P=0.031), the genotypes CT/CC (P=0.030) and the minor allele C (P=0.015) of HBS1L-MYB rs9399137, the genotypes AT/TT (P=0.030) and the minor allele T (P=0.028) of HBS1L-MYB rs4895440, the genotypes AG/GG (P=0.030) and the minor allele G (P=0.028) of HBS1L-MYB rs4895441 (P=0.030) in MaR group were significantly higher than those in MiR and NR groups. Comparing the area under the ROC curve (AUC) of the above indicators to predict the main response, the results demonstrated that the predictive value of baseline HbF level was significantly better than rs7482144 (0.91 vs 0.72, P=0.003), rs9399137 (0.91 vs 0.74, P=0.022), rs4895440 (0.91 vs 0.74, P=0.023) and rs4895441 (0.91 vs 0.74, P=0.023), but there was no significant difference in the predictive value between combined single nucleotide polymorphisms (SNPs) (0.91 vs 0.88, P=0.658）and baseline HbF combined SNPs (0.91 vs 0.97, P=0.132). The AUC value of baseline HbF predicting the efficacy of thalidomide as the main response was 0.91, the cut-off value was 27.4%, the sensitivity was 100%, and the specificity was 58.3% (P=0.001).
Conclusion: The hematologic response of NTDT to thalidomide is variable and complex. Compared to genetic background, baseline HbF may be a simpler and more efficient tool to predict efficacy response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2022.05.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of thalidomide in patients with β-thalassemia intermedia and major.
Medicine (Baltimore)
October 2024
Department of Education Section, Zhongshan Boai Hospital, Zhongshan, China.
To investigate the short-term and long-term efficacy and safety of thalidomide in the treatment of intermediate and severe β-thalassemia. We analyzed patients with intermediate and severe β-thalassemia treated at our hospital from February 2019 to February 2024. Patients who received treatment for more than 3 months were included.
View Article and Find Full Text PDFPozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments.
Orphanet J Rare Dis
August 2024
Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
Article Synopsis
- CHAPLE disease is a rare and serious condition affecting fewer than 100 young people worldwide, characterized by symptoms like abdominal pain and protein loss from the intestines.
- A study used mixed methods, including interviews and clinical assessments, to evaluate the impact of pozelimab treatment on these symptoms over 24 weeks.
- Results showed that after treatment, patients experienced complete resolution of core symptoms, highlighting the value of mixed-methods in understanding patient experiences in rare disease trials.
Clinical efficacy of thalidomide for various genotypes of beta thalassemia.
BMC Med Genomics
July 2024
Department of Eugenics and Genetics, Guilin People's Hospital, No. 12 of Wenming Road, Xiangshan District, Guilin, Guangxi Province, 541002, China.
Objective: The objective of this study was to investigate the therapeutic efficacy of thalidomide across various genotype presentations of β-thalassemia so as to facilitate the early screening of thalidomide-sensitive thalassemia cases and to understand the impact of iron overload on thalidomide.
Methods: From our initial sample of 52 patients, we observed 48 patients with β-thalassemia for two years after administration of thalidomide. This cohort included 34 patients with transfusion-dependent thalassemia (TDT) and 14 patients with non-transfusion-dependent thalassemia (NTDT).
Adaptable Hybrid Beamforming with Subset Optimization Algorithm for Multi-User Massive MIMO Systems.
Sensors (Basel)
June 2024
College of Physical Science and Technology, Yichun University, Yichun 336000, China.
The exploiting of hybrid beamforming (HBF) in massive multiple-input multiple-output (MIMO) systems can enhance the system's sum rate while reducing power consumption and hardware costs. However, designing an effective hybrid beamformer is challenging, and interference between multiple users can negatively impact system performance. In this paper, we develop a scheme called Subset Optimization Algorithm-Hybrid Beamforming (SOA-HBF) that is based on the subset optimization algorithm (SOA), which effectively reduces inter-user interference by dividing the users set into subsets while optimizing the hybrid beamformer to maximize system capacity.
View Article and Find Full Text PDFPersistent albuminuria and chronic kidney disease in adults with sickle cell anaemia: Results from a multicenter natural history study.
Br J Haematol
September 2024
Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Article Synopsis
- * Results showed that 35.7% of participants had PA, with higher rates linked to male sex and ACE inhibitors/ARBs use, while higher hemoglobin levels were associated with a lower likelihood of PA.
- * Additionally, older age and higher alkaline phosphatase levels increased the odds of having a moderate eGFR (60-90), while higher blood pressure and blood urea nitrogen increased the odds of lower
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!